Neurelis Inc v. Lupin Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Neurelis, Inc. (Delaware)
  • Defendant: Lupin Inc. (Delaware), Lupin Ltd. (Republic of India), and Lupin Pharmaceuticals, Inc. (Delaware)
  • Plaintiff's Counsel: McDermott Will & Schulte LLP
• Case Identification: 1:26-cv-00258, D. Del., Filed 03/11/2026
• Venue Allegations: Venue is asserted as proper because two Lupin defendants are Delaware corporations subject to personal jurisdiction, and the third, a non-resident defendant, has allegedly threatened litigation against the Delaware-based plaintiff related to its Abbreviated New Drug Application (ANDA) products.
• Core Dispute: Plaintiff alleges that Defendants' submission of an ANDA to the FDA seeking approval to market a generic version of Plaintiff's VALTOCO® (diazepam nasal spray) constitutes an act of infringement of a patent covering pharmaceutical compositions for intranasal drug delivery.
• Technical Context: The technology relates to formulations for administering benzodiazepines, a class of drugs used to treat seizures, via a nasal spray, offering a rapid and non-invasive alternative to oral or intravenous delivery.
• Key Procedural History: This action was initiated under the Hatch-Waxman Act following a "Third Lupin Notice Letter," in which Lupin notified Neurelis of its ANDA submission and its Paragraph IV certification alleging the patent-in-suit is invalid, not enforceable, and/or not infringed. The complaint notes this case is related to four prior actions, which have been consolidated.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,521,400 - "Administration of Benzodiazepine Compositions"

• Patent Identification: U.S. Patent No. 12,521,400 ("the '400 Patent"), titled "Administration of Benzodiazepine Compositions", issued on January 13, 2026.

The Invention Explained

• Problem Addressed: The patent describes challenges with existing methods of administering benzodiazepine drugs for conditions like seizures ʼ400 Patent, col. 2:1-21 Oral administration is often slow and subject to metabolic breakdown in the liver, potentially requiring large doses ʼ400 Patent, col. 2:1-5 Intravenous delivery is faster but requires trained professionals and is impractical outside of a clinical setting ʼ400 Patent, col. 2:8-15 Suppositories, while effective, are noted as inconvenient ʼ400 Patent, col. 2:16-21
• The Patented Solution: The invention provides a pharmaceutical composition for intranasal administration that dissolves a benzodiazepine drug, such as diazepam, in a carrier system comprising tocopherols (a class of Vitamin E compounds) and one or more alcohols ʼ400 Patent, abstract ʼ400 Patent, col. 2:23-32 This formulation is designed for delivery as a nasal spray, enabling rapid absorption through the nasal mucosal membranes and bypassing the digestive system and first-pass liver metabolism ʼ400 Patent, col. 16:11-17
• Technical Importance: This approach provides a non-invasive, rapid-acting delivery method for seizure-rescue medication that can be administered by caregivers outside of a hospital, which is significant for the acute treatment of seizure clusters ʼ400 Patent, col. 1:40-45

Key Claims at a Glance

• The complaint asserts infringement of claims 1-21 Compl. ¶39 Independent claim 1 is exemplified in the complaint Compl. ¶40
• Essential Elements of Independent Claim 1:
  • A pharmaceutical composition for intranasal administration comprising:
  • about 1 to about 20 mg of diazepam dissolved in
  • about 45% to about 85% (w/w) of one or more natural or synthetic tocopherols or tocotrienols selected from a specified group,
  • and about 25% to about 40% (w/w) of one or more alcohols selected from a specified group,
  • wherein the pharmaceutical composition is a solution of 50 µL to 150 µL,
  • and wherein the pharmaceutical composition is in a pharmaceutically-acceptable spray formulation for intranasal administration.
• The complaint reserves the right to assert other claims Compl. ¶39

III. The Accused Instrumentality

Product Identification

The accused products are Lupin's generic versions of VALTOCO® (diazepam nasal spray), for which Lupin submitted ANDA No. 220394 to the FDA Compl. ¶1 The ANDA covers dosages of 5 mg/spray, 7.5 mg/spray, and 10 mg/spray Compl. ¶1

Functionality and Market Context

• The Lupin ANDA Products are intended to be a generic equivalent to VALTOCO®, a prescription nasal spray rescue medicine for the short-term treatment of seizure clusters in epilepsy patients Compl. ¶1 Compl. ¶24
• The complaint alleges that Lupin seeks FDA approval to commercially manufacture, use, and sell these products in the United States prior to the expiration of the '400 Patent Compl. ¶1 The act of infringement alleged is the submission of the ANDA itself, which under 35 U.S.C. § 271(e)(2) is a technical act of infringement for the purpose of establishing jurisdiction in a Hatch-Waxman case Compl. ¶39

IV. Analysis of Infringement Allegations

The complaint alleges that Lupin's ANDA Products literally infringe or, alternatively, infringe under the doctrine of equivalents, but does not provide a detailed, element-by-element mapping of the accused product to the asserted claims Compl. ¶41 It instead makes a general allegation that the products "satisfy at least each of the claim limitations exemplified in Claim 1" Compl. ¶41 Without a specific breakdown of the accused product's formulation, a claim chart summary cannot be constructed. The core of the infringement allegation is that by filing an ANDA for a product bioequivalent to VALTOCO®, which is listed in the FDA's Orange Book as being covered by the '400 Patent, Lupin has committed an act of infringement Compl. ¶27 Compl. ¶39

No probative visual evidence provided in complaint.

Identified Points of Contention

• Scope Questions: A central question will be whether the specific formulation detailed in Lupin's ANDA falls within the claimed ranges for its components. For example, does Lupin's product contain "about 45% to about 85% (w/w)" of a tocopherol and "about 25% to about 40% (w/w)" of an alcohol, as required by claim 1? The complaint does not contain these details, which will be a focus of discovery.
• Technical Questions: The complaint's alternative allegation of infringement under the doctrine of equivalents raises the question of whether any components or concentrations in Lupin's formulation that differ from the literal claim language could be argued to perform the same function, in the same way, to achieve the same result Compl. ¶41

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for a full analysis of claim construction disputes. However, based on the patent's specification, certain terms may become central to the litigation.

• The Term: "dissolved in"
• Context and Importance: Claim 1 requires that the diazepam be "dissolved in" the tocopherol and alcohol carrier. Practitioners may focus on this term because the patent specification distinguishes between compositions where the drug is fully dissolved in a solvent and those where it exists as a particulate suspension (e.g., microparticles or nanoparticles) ʼ400 Patent, col. 2:40-46 ʼ400 Patent, col. 8:30-38 The physical state of the diazepam in Lupin's formulation-whether it is a true solution or another form like an emulsion or suspension-will make the construction of this term critical to determining literal infringement.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: A party could argue for the term's plain and ordinary meaning, which might encompass states beyond a classic, single-phase solution, depending on the technical context. The patent does not provide an explicit definition that limits the term.
  • Evidence for a Narrower Interpretation: The specification repeatedly refers to creating a "solution" and contrasts this with compositions containing "benzodiazepine microparticles, nanoparticles or combinations thereof" ʼ400 Patent, claim 1 ʼ400 Patent, col. 2:42-43 This language suggests an intended distinction and could support an interpretation that "dissolved in" requires the drug to be fully incorporated into the solvent phase, thereby excluding suspensions.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon FDA approval, Lupin will actively induce infringement by marketing and selling the ANDA Products for their intended use and will contributorily infringe the '400 Patent Compl. ¶42
• Willful Infringement: The complaint alleges that Lupin acted with "full knowledge of the '400 patent and its claims" based on its Paragraph IV certification and notice letter Compl. ¶43 It further alleges Lupin proceeded "without a reasonable basis for believing that it would not be liable for direct or indirect... infringement" Compl. ¶43

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of compositional fact: does the precise formulation of Lupin's generic diazepam nasal spray, as disclosed in its confidential ANDA filing, literally meet the specific weight-percentage ranges of tocopherols and alcohols required by the asserted claims? The outcome of the literal infringement analysis will depend entirely on facts not yet public.
• A key legal question will be one of definitional scope: how will the court construe the term "dissolved in"? The patent's distinction between solutions and particulate suspensions suggests this term may be interpreted narrowly, which could be dispositive if Lupin's formulation is not a true, single-phase solution.